- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | LIXTE Biotechnology prices $16.6M registered direct offering | 1 | Seeking Alpha | ||
| LIXTE BIOTECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| Mi | Lixte Biotechnology raises $16.6 million in direct offering | 2 | Investing.com | ||
| Mi | Lixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Announces $16,566,027 Registered Direct Offering Priced at the Market Under Nasdaq Rules, Strengthening Balance Sheet for Next Phase of Strategic Growth | 1 | GlobeNewswire (USA) | ||
| Mo | Lixte Biotechnology Shares Slip 6% Despite Pivot To AI Energy Infrastructure Business | 1 | RTTNews | ||
| Mo | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| Mo | Lixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Announces Strategic Transformation into AI Energy Infrastructure Equipment & Services; Stuart D. Porter, Founder of Denham Capital, to Join Board of Directors | 98 | GlobeNewswire (Europe) | Bringing More Than Three Decades of Energy Investment Experience, Mr. Porter Has Helped Build a Global Power Infrastructure Portfolio, Strengthening LIXTE's Strategic Expansion into AI Energy Infrastructure... ► Artikel lesen | |
| 14.05. | Lixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Files First Quarter 2026 Quarterly Report on Form 10-Q; Provides Operational Progress Update | 170 | GlobeNewswire (Europe) | BOCA RATON, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (Nasdaq: LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing... ► Artikel lesen | |
| 14.05. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 17.04. | Lixte Biotechnology stellt Vergütung für Management um: RSUs ersetzen Aktienoptionen | 5 | Investing.com Deutsch | ||
| 17.04. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 31.03. | Lixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Files 2025 Annual Report on Form 10K, Provides Operational Highlights of Transformative Year | 620 | GlobeNewswire (Europe) | BOCA RATON, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (Nasdaq: LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing... ► Artikel lesen | |
| 31.03. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 10-K, Annual Report | - | SEC Filings | ||
| 20.03. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.03. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.02. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.02. | Lixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. Subsidiary | 519 | GlobeNewswire (Europe) | BOCA RATON, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (Nasdaq: LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing... ► Artikel lesen | |
| 21.01. | Lixte Biotechnology Holdings, Inc.: DE LA SOUL-LED "GOOD HEALTH SUMMIT" LAUNCHES FEBRUARY 19 AT MOREHOUSE COLLEGE | 3 | GlobeNewswire (USA) | ||
| 31.12.25 | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 23.12.25 | LIXTE erweitert Studie zur Behandlung von Ovarialkarzinom | 1 | Investing.com Deutsch | ||
| 22.12.25 | Spartan Capital acts as placement agent in Lixte's $4.3 million offering | 2 | Investing.com |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 77,05 | -1,34 % | BioNTech und BMS melden neue Daten für Lungenkrebskandidat Pumitamig | BioNTech SE und Bristol Myers Squibb haben auf dem ASCO-Jahreskongress in Chicago erste globale Phase-2-Daten für den bispezifischen Immunmodulator Pumitamig in Kombination mit Chemotherapie bei fortgeschrittenem... ► Artikel lesen | |
| EVOTEC | 4,932 | -3,58 % | EQS-News: Evotec SE: Evotec ernennt Rui Wang zum Head of Global In Silico & AI | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Evotec ernennt Rui Wang zum Head of Global In Silico & AI
02.06.2026 / 07:30 CET/CEST
Für den Inhalt der Mitteilung ist... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 44,705 | -0,60 % | CRISPR Therapeutics AG (CRSP): One of The most Shorted Mid Cap Stocks to Buy on Robust Gene Editing Pipeline | ||
| OCUGEN | 1,118 | +0,18 % | Ocugen, Inc. - 8-K, Current Report | ||
| INOVIO PHARMACEUTICALS | 0,932 | +0,87 % | H.C. Wainwright senkt Kursziel für Inovio wegen höherer Aktienanzahl | ||
| VIKING THERAPEUTICS | 24,650 | -0,20 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| IMMUNITYBIO | 6,070 | +1,17 % | ImmunityBio Inc. (IBRX): One of the Most Shorted Mid-Cap Stocks to Buy Now | ||
| RECURSION PHARMACEUTICALS | 3,315 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports First Quarter Financial Results and Provides Business Update | Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable... ► Artikel lesen | |
| MARINOMED BIOTECH | 9,550 | 0,00 % | Marinomed lizenziert Marinosolv-Technologie für Inhalationstherapie | Die Marinomed Biotech AG hat ein Term Sheet mit der Phargentis SA über eine weltweite exklusive Lizenz der Marinosolv-Technologieplattform für eine nicht näher genannte Inhalationsformulierung unterzeichnet.... ► Artikel lesen | |
| CEL-SCI | 1,270 | +4,10 % | Cel-Sci GAAP EPS of -$1.35 | ||
| ORAGENICS | 0,595 | +0,61 % | Oragenics, Inc.: Oragenics Signs Letter of Intent to License CardioDialysis Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation | The Expected License Agreement Would Position Oragenics as the Only Company with Therapeutic Strategies Targeting TBI-Induced Inflammation on Both Sides of the Blood-Brain Barrier Sarasota, FL and... ► Artikel lesen | |
| CAPRICOR | 23,170 | 0,00 % | Deramiocel Outlook Strengthens Capricor Therapeutics, Inc. (CAPR) as a Small-Cap Stock to Buy | ||
| REVIVE THERAPEUTICS | 0,019 | +22,58 % | Revive Therapeutics Ltd.: Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures | Company to advance additional preclinical studies and pursue government partnership opportunities for bucillamine as a potential franchise asset for infectious diseases, nerve-agent exposure, future... ► Artikel lesen | |
| KYNTRA BIO | 5,800 | -2,52 % | Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update | Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is progressing well with the... ► Artikel lesen | |
| ZEVRA THERAPEUTICS | 9,720 | +5,42 % | ZEVRA THERAPEUTICS, INC. - 8-K, Current Report |
Das Unternehmen LIXTE BIOTECHNOLOGY HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +0,57 % bei einem Aktienkurs von 7,040 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LIXTE BIOTECHNOLOGY HOLDINGS INC finden Sie auf Wallstreet Online.